Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2168681 | 0.90 | NPSR1 (0.39) | EPHX2L3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL2169773 | 0.86 | EPHX2 (0.38) | EPHX2MAPTHSD11B1SMN1; SMN2CNR2 | |
| SCHEMBL2169223 | 0.85 | EPHX2 (0.37) | EPHX2MAPTHSD11B1MGLLSMN1; SMN2 | |
| SCHEMBL2168936 | 0.85 | HSD11B1 (0.41) | HSD11B1CNR2 | |
| SCHEMBL2168931 | 0.85 | HSD11B1 (0.41) | HSD11B1CNR2 | |
| SCHEMBL12012579 | 0.85 | HSD11B1 (0.41) | HSD11B1CNR2 | |
| SCHEMBL2176939 | 0.84 | KMT2A (0.44) | MAPTMEN1KMT2AHSD11B1MGLL | |
| SCHEMBL2169491 | 0.83 | ELANE (0.40) | EPHX2ELANEMAPTMEN1KMT2A | |
| SCHEMBL13368871 | 0.83 | EPHX2 (0.36) | EPHX2HSD11B1CNR2USP2 | |
| SCHEMBL2170619 | 0.82 | ALOX12 (0.38) | EPHX2ELANEMEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | claimed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | claimed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | claimed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| WO-2010050191-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | 興和株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | EPHX2 2371/4885ELANE 1217/4885L3MBTL1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.